LEGN

Legend Biotech Corp: Q3 2025 Financial Summary

Business Context and Reporting Period

This Form 6-K reports the unaudited interim condensed consolidated financial results for Legend Biotech Corporation for the three and nine months ended September 30, 2025. Legend is a global biopharmaceutical company focused on cell therapies, with its primary commercial product being CARVYKTI (ciltacabtagene autoleucel), developed in collaboration with Janssen Biotech, Inc. (Johnson & Johnson). The company operates manufacturing and commercialization activities in the U.S., Europe, and China.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 64% year-over-year (YoY) to $722.5 million for the nine months ended September 30, 2025, compared to $440.7 million in 2024. This was driven primarily by a 112% increase in collaboration revenue ($667.2 million vs. $314.6 million) due to higher CARVYKTI sales.
• License Revenue Decline: License revenue decreased 54% YoY to $55.2 million. This was largely due to the absence of $75.1 million in milestone payments recognized in the prior year under the Janssen Agreement, partially offset by $20.0 million in related-party sublicense revenue.
• Expense Increases: Selling and distribution expenses rose 44% YoY to $141.6 million, reflecting sales force expansion and marketing activities. Research and development expenses remained relatively flat, increasing slightly to $313.4 million.
• Foreign Exchange Impact: The company reported a significant unrealized foreign exchange loss of $165.4 million in "Other income/(expense), net," compared to a gain of $0.5 million in the prior year. This volatility is attributed to exchange rate fluctuations between the USD and EUR affecting intercompany loans and cash balances.
• Net Loss: Reported net loss widened to $266.0 million from $203.3 million in the prior year, primarily due to the foreign exchange loss and increased operating costs, despite higher revenue.

Guidance, Outlook, and Risks

• Profitability Outlook: Management expects the CARVYKTI collaboration to achieve a profitable position by the end of 2025. Consequently, the recoupment of $250 million in Janssen funding advances (plus accrued interest) will be triggered from collaboration pre-tax profits starting in the first quarter following the first profitable year.
• Liquidity: With approximately $1.0 billion in cash, cash equivalents, and time deposits, the company believes it has sufficient resources to meet operational and loan repayment needs for at least the next 12 months.
• Regulatory & Tax: The company evaluated the impact of the U.S. "One Big Beautiful Bill Act" (signed July 4, 2025) and concluded there was no material effect on its financial statements for the period.
• Risks: Key risks include potential future tariffs on pharmaceutical ingredients (though current U.S. supply is domestic), macroeconomic inflation, and the uncertainty of clinical trial results for pipeline candidates. The company does not currently hedge foreign exchange risk.

Investor Verification Checklist

• Foreign Exchange Volatility: Verify the magnitude of unrealized FX losses ($165.4 million) and their impact on reported net loss versus Adjusted Net Loss ($35.7 million).
• Janssen Recoupment Trigger: Confirm the timeline for the collaboration reaching profitability and the subsequent repayment schedule of the $314.8 million in advanced funding.
• License Revenue Sustainability: Assess the reliance on milestone payments versus recurring revenue, noting the significant drop in license revenue due to the timing of Janssen milestones.
• Operating Cash Burn: Review the $88.0 million cash used in operating activities and the company's ability to sustain this burn rate given the $1.0 billion liquidity position.
• Manufacturing Expansion: Verify the costs associated with the new commercial production facility in Belgium and its impact on future cost of sales.